Safety and effect of topical recombinant human interleukin‐1β in the management of pressure sores

M. C. Robson, A. Abdullah, B. F. Burns, Linda Phillips, L. Garrison, W. Cowan, D. Hill, J. Vandeberg, L. E. Robson, S. Scheeler

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Interleukin‐1β is produced by numerous cell types including monocytes and fibroblasts. It has been shown to stimulate multiple cell types including fibroblasts, keratinocytes, endothelial cells, neutrophils, macrophages, and lymphocytes. Previously, interleukin‐1β was shown to accelerate healing in partial‐thickness and full‐thickness wounds in animals and was also shown to be safe when applied topically in Phase I human trials. Therefore a prospectively randomized, blind, placebo‐controlled trial was performed with patients with chronic pressure ulcers. Doses of interleukin‐1β of .01 µg, .10 µg, and 1.0 µg per square centimeter did not show acceleration of healing of the pressure ulcers. Therefore use of recombinant human interleukin‐1β in this study was safe but, at the dose levels tested, did not result in improvement in the healing ratio.

Original languageEnglish (US)
Pages (from-to)177-181
Number of pages5
JournalWound Repair and Regeneration
Volume2
Issue number3
DOIs
StatePublished - 1994

Fingerprint

Pressure Ulcer
Fibroblasts
Safety
Keratinocytes
Monocytes
Neutrophils
Endothelial Cells
Macrophages
Lymphocytes
Wounds and Injuries

ASJC Scopus subject areas

  • Surgery
  • Dermatology

Cite this

Safety and effect of topical recombinant human interleukin‐1β in the management of pressure sores. / Robson, M. C.; Abdullah, A.; Burns, B. F.; Phillips, Linda; Garrison, L.; Cowan, W.; Hill, D.; Vandeberg, J.; Robson, L. E.; Scheeler, S.

In: Wound Repair and Regeneration, Vol. 2, No. 3, 1994, p. 177-181.

Research output: Contribution to journalArticle

Robson, MC, Abdullah, A, Burns, BF, Phillips, L, Garrison, L, Cowan, W, Hill, D, Vandeberg, J, Robson, LE & Scheeler, S 1994, 'Safety and effect of topical recombinant human interleukin‐1β in the management of pressure sores', Wound Repair and Regeneration, vol. 2, no. 3, pp. 177-181. https://doi.org/10.1046/j.1524-475X.1994.20307.x
Robson, M. C. ; Abdullah, A. ; Burns, B. F. ; Phillips, Linda ; Garrison, L. ; Cowan, W. ; Hill, D. ; Vandeberg, J. ; Robson, L. E. ; Scheeler, S. / Safety and effect of topical recombinant human interleukin‐1β in the management of pressure sores. In: Wound Repair and Regeneration. 1994 ; Vol. 2, No. 3. pp. 177-181.
@article{3192415881e44b50a24283115a1b85c7,
title = "Safety and effect of topical recombinant human interleukin‐1β in the management of pressure sores",
abstract = "Interleukin‐1β is produced by numerous cell types including monocytes and fibroblasts. It has been shown to stimulate multiple cell types including fibroblasts, keratinocytes, endothelial cells, neutrophils, macrophages, and lymphocytes. Previously, interleukin‐1β was shown to accelerate healing in partial‐thickness and full‐thickness wounds in animals and was also shown to be safe when applied topically in Phase I human trials. Therefore a prospectively randomized, blind, placebo‐controlled trial was performed with patients with chronic pressure ulcers. Doses of interleukin‐1β of .01 µg, .10 µg, and 1.0 µg per square centimeter did not show acceleration of healing of the pressure ulcers. Therefore use of recombinant human interleukin‐1β in this study was safe but, at the dose levels tested, did not result in improvement in the healing ratio.",
author = "Robson, {M. C.} and A. Abdullah and Burns, {B. F.} and Linda Phillips and L. Garrison and W. Cowan and D. Hill and J. Vandeberg and Robson, {L. E.} and S. Scheeler",
year = "1994",
doi = "10.1046/j.1524-475X.1994.20307.x",
language = "English (US)",
volume = "2",
pages = "177--181",
journal = "Wound Repair and Regeneration",
issn = "1067-1927",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Safety and effect of topical recombinant human interleukin‐1β in the management of pressure sores

AU - Robson, M. C.

AU - Abdullah, A.

AU - Burns, B. F.

AU - Phillips, Linda

AU - Garrison, L.

AU - Cowan, W.

AU - Hill, D.

AU - Vandeberg, J.

AU - Robson, L. E.

AU - Scheeler, S.

PY - 1994

Y1 - 1994

N2 - Interleukin‐1β is produced by numerous cell types including monocytes and fibroblasts. It has been shown to stimulate multiple cell types including fibroblasts, keratinocytes, endothelial cells, neutrophils, macrophages, and lymphocytes. Previously, interleukin‐1β was shown to accelerate healing in partial‐thickness and full‐thickness wounds in animals and was also shown to be safe when applied topically in Phase I human trials. Therefore a prospectively randomized, blind, placebo‐controlled trial was performed with patients with chronic pressure ulcers. Doses of interleukin‐1β of .01 µg, .10 µg, and 1.0 µg per square centimeter did not show acceleration of healing of the pressure ulcers. Therefore use of recombinant human interleukin‐1β in this study was safe but, at the dose levels tested, did not result in improvement in the healing ratio.

AB - Interleukin‐1β is produced by numerous cell types including monocytes and fibroblasts. It has been shown to stimulate multiple cell types including fibroblasts, keratinocytes, endothelial cells, neutrophils, macrophages, and lymphocytes. Previously, interleukin‐1β was shown to accelerate healing in partial‐thickness and full‐thickness wounds in animals and was also shown to be safe when applied topically in Phase I human trials. Therefore a prospectively randomized, blind, placebo‐controlled trial was performed with patients with chronic pressure ulcers. Doses of interleukin‐1β of .01 µg, .10 µg, and 1.0 µg per square centimeter did not show acceleration of healing of the pressure ulcers. Therefore use of recombinant human interleukin‐1β in this study was safe but, at the dose levels tested, did not result in improvement in the healing ratio.

UR - http://www.scopus.com/inward/record.url?scp=84989104603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989104603&partnerID=8YFLogxK

U2 - 10.1046/j.1524-475X.1994.20307.x

DO - 10.1046/j.1524-475X.1994.20307.x

M3 - Article

AN - SCOPUS:84989104603

VL - 2

SP - 177

EP - 181

JO - Wound Repair and Regeneration

JF - Wound Repair and Regeneration

SN - 1067-1927

IS - 3

ER -